- Verastem Oncology (VSTM, Financial) announces 83% overall response rate in Phase 1/2 RAMP 205 trial.
- Plans underway for registrational Phase 3 study for metastatic pancreatic ductal adenocarcinoma.
- Verastem to host investor webcast on June 2 to review updated data and future plans.
Verastem Oncology (VSTM), a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, has announced positive results from its RAMP 205 Phase 1/2 trial. The trial evaluates avutometinib and defactinib in combination with standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The dose level 1 cohort achieved an impressive 83% overall response rate (ORR) among patients, with 10 out of 12 participants showing partial responses. This cohort was chosen as the recommended Phase 2 dose.
Given these significant results, Verastem is progressing with plans for a registrational Phase 3 study expected to launch in 2026. In addition, the company will conduct an investor webcast on June 2 to discuss these findings and present updates on the VS-7375 study, a collaboration with GenFleet Therapeutics. This event will feature insights from Verastem’s management and key opinion leaders.
Verastem's commitment to advancing cancer treatments is further highlighted by the recent FDA approval of the AVMAPKIâ„¢ FAKZYNJAâ„¢ co-pack for KRAS-mutated recurrent low-grade serous ovarian cancer, marking a significant step forward in the treatment of this condition. The company continues to explore additional market opportunities for its therapeutic combinations, aiming to address other advanced solid tumors.
